Pharmacology
Summary
Osteoporosis is a condition characterized by weakened bones and an increased risk of fractures. Various drugs are used to treat osteoporosis, each with distinct mechanisms of action and benefits.
Parathyroid Hormone (PTH) is central to calcium regulation and bone health, and it stimulates active vitamin D production, which is essential for calcium absorption and bone mineralization. Calcitriol, which is derived from vitamin D, is responsible for maintaining calcium-phosphate balance and is used clinically to enhance absorption, reabsorption, and bone health. Vitamin D supplements are vital in cases of deficiency and can treat conditions like osteoporosis and psoriasis, though toxicities can occur.
Teriparatide, a synthetic PTH, stimulates osteoblast activity and bone formation. It's administered through injections and is effective in treating severe osteoporosis by fostering bone growth, which sets it apart from other treatments. Cinacalcet, a calcimimetic, moderates parathyroid function by altering calcium-sensing receptors, which is useful in managing hypercalcemia due to hyperparathyroidism.
Sevelamer, a phosphate binder, aids in managing kidney disease-associated hyperphosphatemia by reducing phosphate absorption. In unison, these treatments provide a comprehensive approach to bone health and calcium regulation.
Lesson Outline
Don't stop here!
Get access to 133 more Pharmacology lessons & 13 more medical school learning courses with one subscription!
FAQs
Teriparatide is a recombinant form of parathyroid hormone used in the treatment of osteoporosis. It is particularly effective in postmenopausal women and men who are at high risk for fractures. The drug functions by stimulating osteoblasts, the cells responsible for bone formation, thereby promoting bone growth and improving bone density.
Vitamin D is instrumental in maintaining calcium and phosphate homeostasis in the body by facilitating the absorption of these minerals from the gut and kidneys, leading to increased serum levels. Vitamin D also works in conjunction with the parathyroid hormone to maintain bone health, as its deficiency could lead to conditions like rickets in children or osteomalacia in adults.
Cinacalcet is a calcimimetic drug primarily used in the treatment of secondary hyperparathyroidism and parathyroid carcinoma. It functions by enhancing the sensitivity of the calcium-sensing receptor on the parathyroid gland to the existing blood calcium levels, leading to a reduction in parathyroid hormone secretion. This subsequently results in lower levels of calcium and phosphorus in the blood.
Sevelamer is a phosphate binder used to manage hyperphosphatemia, primarily in patients with chronic kidney disease (CKD) who are on dialysis. It works by binding to dietary phosphate in the gut, which is then excreted, resulting in lower serum phosphate levels. Sevelamer does not contain calcium, so it does not contribute to calcification, a common concern in CKD patients.
MCAT® is a registered trademark of the Association of American Medical Colleges. The United States Medical Licensing Examination (USMLE®) is a joint program of the Federation of State Medical Boards (FSMB®) and National Board of Medical Examiners (NBME®). NAPLEX® is a registered trademark of the National Association of Boards of Pharmacy. PANCE© is a registered trademark of the National Commission on Certification of Physician Assistants. NCLEX® is a registered trademark and service mark of the National Council of State Boards of Nursing, Inc. None of the trademark holders are endorsed by nor affiliated with Sketchy or this website.
